D.E. Shaw & Co
RLMD icon

D.E. Shaw & Co’s Relmada Therapeutics RLMD Stock Holding History

D.E. Shaw & Co’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,649
Closed -$44.1K – 4669
2023
Q4 		$44.1K Sell
10,649
-8,829
-45% -$26.1K ﹤0.01% 4029
2023
Q3 		$58.4K Sell
19,478
-23,239
-54% -$69K ﹤0.01% 3905
2023
Q2 		$105K Sell
42,717
-1,245
-3% -$3.44K ﹤0.01% 3824
2023
Q1 		$99.4K Buy
43,962
+28,290
+181% +$97.5K ﹤0.01% 3982
2022
Q4 		$54.7K Sell
15,672
-62,534
-80% -$549K ﹤0.01% 4430
2022
Q3 		$2.9M Buy
+78,206
New +$2.17M ﹤0.01% 2669
2022
Q2 		– Sell
-10,487
Closed -$283K – 5705
2022
Q1 		$283K Buy
+10,487
New +$217K ﹤0.01% 4682

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co's RLMD Position: Q1 2024 in Review

D.E. Shaw & Co sold out of Relmada Therapeutics (RLMD) in Q1 2024, closing a stake of 10,649 shares — an estimated $44.1K sold.

D.E. Shaw & Co first reported a position in RLMD in Q1 2022 and held it in 7 quarters. The position peaked at $2.9M in Q3 2022. 93 funds tracked by Wall St. Rank hold RLMD as of Q1 2024.

  • D.E. Shaw & Co reported no remaining Relmada Therapeutics position as of Q1 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 10,649 Relmada Therapeutics shares in Q1 2024, an estimated $44.1K.
  • D.E. Shaw & Co first reported a position in Relmada Therapeutics in Q1 2022 and held it in 7 quarters.
  • D.E. Shaw & Co's Relmada Therapeutics position peaked at $2.9M in Q3 2022.
  • 93 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.